Cargando…
Loading, please waitWhat CJC-1295 and Ipamorelin are, how the GH secretagogue stack works, clinical evidence, typical dosing, and COFEPRIS regulatory context.
CJC-1295 and Ipamorelin are two of the most discussed peptides in the growth hormone (GH) conversation, and they almost always appear together. They are not interchangeable, and they are not the same molecule as growth hormone itself. They are growth hormone secretagogue peptides, meaning they prompt your own pituitary gland to release the GH it is already capable of producing.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends to the pituitary. CJC-1295 exists in two formulations that are routinely confused, including in marketing copy. The original "CJC-1295 with DAC" (Drug Affinity Complex) was designed to bind to plasma albumin, giving it a long half-life of roughly six to eight days and producing a sustained elevation of GH and IGF-1. The more commonly prescribed form in clinical practice today, often called "CJC-1295 without DAC" or Modified GRF (1-29), is a 29-amino-acid GHRH fragment with a half-life of around thirty minutes. The short half-life is, counterintuitively, a feature: it preserves the body's natural pulsatile pattern of GH release rather than flattening it.
Ipamorelin is a pentapeptide ghrelin receptor agonist, in the same family of "GHRPs" (growth hormone-releasing peptides) as GHRP-2 and GHRP-6, but considerably more selective. Where older GHRPs also stimulate cortisol, prolactin, and appetite, Ipamorelin acts almost exclusively on the GH-release pathway, which is why it largely replaced its predecessors in clinical protocols.
Used together, CJC-1295 and Ipamorelin work on two different receptors in the pituitary and produce a synergistic, amplified GH pulse. This is the "CJC-1295 Ipamorelin" stack that has become the default growth hormone secretagogue peptides protocol in regenerative medicine clinics worldwide.
The conventional way to elevate GH levels in adults has been recombinant human growth hormone (rhGH), administered as a daily exogenous injection. rhGH bypasses the pituitary entirely and replaces the hormone directly, which works but has a meaningful clinical cost: it suppresses the pituitary feedback loop, requires careful IGF-1 monitoring, and produces a flat, non-physiologic exposure profile.
The CJC-1295 + Ipamorelin approach is mechanistically different. By stimulating the pituitary through two complementary receptors, GHRH and ghrelin, the stack triggers the body's own GH release while preserving the pulsatile rhythm. In healthy adults, GH is released in discrete pulses, primarily during the first hours of deep sleep. Restoring or amplifying those pulses, rather than overriding them, is the rationale for choosing a secretagogue protocol over exogenous GH.
The downstream effects of an elevated GH pulse are well-characterized in endocrinology: increased hepatic IGF-1 production, lipolysis in adipose tissue, support for lean muscle protein synthesis, and modulation of slow-wave sleep architecture. Whether peptide-induced GH pulses translate into clinically meaningful changes in body composition, recovery, and sleep in otherwise healthy adults is a separate question, and the honest answer is the subject of the next section.
The published evidence for CJC-1295 and Ipamorelin is uneven, and it is worth being precise about what we know and where the data thin out.
CJC-1295 (with DAC) pharmacokinetics. The 2006 pharmacokinetic and pharmacodynamic studies of CJC-1295 with DAC in healthy adults are the cleanest data we have. They demonstrate dose-dependent, sustained elevations of GH and IGF-1 over multiple days after a single dose. This is mechanism-confirming evidence that the molecule does what it is designed to do.
Ipamorelin clinical evidence. Ipamorelin has been studied in several clinical contexts, including a Phase 2B trial for postoperative ileus, where it failed to meet its primary endpoint, and earlier work demonstrating selective GH release without significant cortisol or prolactin effect. The selective receptor profile is well-established. What is less established is whether Ipamorelin produces clinically meaningful outcomes in non-deficient adults seeking recovery, sleep, or body composition benefits.
The combination protocol. Here the published evidence is thinner than the marketing suggests. Most of what supports the "CJC-1295 + Ipamorelin" combination comes from mechanism plausibility, pharmacokinetic modeling, small open-label series, and clinical experience, rather than from large randomized controlled trials in healthy adults. Anti-aging and recovery claims are largely extrapolated from GH and IGF-1 physiology, not directly from head-to-head trials of this specific stack.
Peptide therapy for recovery sleep. The link between GH pulses and slow-wave sleep is biologically real, and some patients on secretagogue protocols report subjectively better sleep quality. This is a reasonable expectation based on physiology, but it is not the same as a placebo-controlled trial demonstrating sleep architecture changes from this specific protocol.
The honest summary, as of 2026, is that the CJC-1295 + Ipamorelin stack rests on strong mechanistic logic, well-characterized component pharmacology, and a real but limited body of clinical outcome data. It is reasonable to consider in selected patients within a supervised plan. It is not appropriate to present as a validated anti-aging therapy with established outcomes.
For broader context on how this peptide fits among others, our beginner's guide to peptide therapy covers the landscape, and our discussion of BPC-157 evidence in 2026 applies the same evidentiary discipline to a different molecule.
Specific dosing belongs in a physician's office, not in a blog post, and any protocol described here is illustrative rather than prescriptive. That said, the general structure of a GH peptide protocol Mexico clinics use looks like this:
What no responsible protocol looks like: a flat dose for everyone, no labs, no follow-up, no contraindication screening, and no conversation about expectations. If that is what is being offered, it is not clinical peptide therapy.
Growth hormone pathways touch many systems, which is precisely why GH secretagogue peptides require screening before prescription. The categories where CJC-1295 and Ipamorelin are contraindicated or require special caution include:
Side effects in appropriate candidates are generally mild and dose-dependent: transient injection-site reactions, occasional flushing or lightheadedness shortly after dosing, vivid dreams, and water retention. Persistent paresthesias, joint discomfort, or rising fasting glucose are signals to reduce dose or stop, and reasons monitoring labs exist.
In Mexico, peptide therapy operates under a specific regulatory framework that is worth understanding before any patient agrees to a protocol. The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) regulates pharmaceutical substances and the clinical environments in which they are administered.
As of 2026, neither CJC-1295 nor Ipamorelin is a COFEPRIS-registered finished pharmaceutical product with an approved indication for anti-aging, recovery, or body composition. They are accessed through licensed compounding pharmacies operating under the *farmacia magistral* framework, the same framework that governs custom-formulated medications across many therapeutic categories.
In practice this means three things any Mexican patient should expect:
This is the regulatory posture we operate under at Regeneris Therapy, and it is the posture any patient should expect from any serious clinic offering GH peptide protocol Mexico services.
There is no universal candidate for GH secretagogue peptides, and there is no version of this conversation where the answer is "everyone over forty." Based on current evidence and our clinical experience, the patients most likely to be appropriate are:
The patients for whom this is not appropriate are equally important to name: anyone seeking a quick fix instead of doing the work, anyone whose primary issue is undiagnosed sleep apnea or thyroid dysfunction, anyone with the contraindications listed above, and anyone whose expectations have been set by social media rather than by a physician.
CJC-1295 and Ipamorelin, used as a supervised stack in selected patients, are a reasonable tool within the regenerative medicine and longevity conversation. They are not a replacement for the boring fundamentals, sleep, training, nutrition, and stress management, that make any GH protocol either useful or pointless. Used responsibly, they support physiology already in motion. Used as a shortcut around the fundamentals, they will disappoint.
If you are considering peptide therapy in Cancún or elsewhere in Mexico, the right first step is a physician evaluation with appropriate labs, not a product order from an online vendor. You can reach our team through our contact page to schedule a consultation, or learn more about our peptide therapy services at /peptides/en. Our medical team is happy to discuss whether this protocol is appropriate for your specific clinical picture.
Keep reading
A no-hype, step-by-step walkthrough of what stem cell treatment in Cancún actually involves, from medical evaluation to follow-up, so you know what happens before you book a trip.
An honest, evidence-based look at how regenerative medicine is being used for chronic and autoimmune conditions, what the science supports, where it is still emerging, and who may be a candidate.
A clinical, non-promotional guide to stem cell therapy for hip osteoarthritis — how MSCs work in the hip joint, what the WOMAC and VAS data realistically show, who is a candidate, when replacement is the better call, and how the evaluation works.
Speak with our care team in Cancún about a personalized plan.
Talk to our medical team
